Barclays reiterated coverage on Ligand Pharmaceuticals with a new price target

5/4/21 10:16:58 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Barclays reiterated coverage of Ligand Pharmaceuticals with a rating of Overweight and set a new price target of $190.00 from $198.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LGND

Date	Price Target	Rating	Analyst
4/10/2025	$143.00	Buy	Stifel
10/3/2024	$135.00	Outperform	Oppenheimer
7/30/2024	$130.00	Outperform	RBC Capital Mkts
2/22/2022	$180.00 → $130.00	Buy	Benchmark
2/18/2022	$185.00 → $165.00	Overweight	Barclays
9/22/2021	$174.00 → $180.00	Overweight	Barclays
7/30/2021	$200.00 → $190.00	Buy	Roth Capital